Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

From HER2 to herceptin.

K Mokbel1, D Hassanally

  • 1St George's Hospital, Blackshaw Road, London SW17 0QT, UK. kefahmokbel@hotmail.com

Current Medical Research and Opinion
|July 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter re: A critical appraisal of the DATA trial analysis on the prognostic and predictive value of the luminal-like subtype.

ESMO open·2025
Same author

Unilateral axillary adenopathy following COVID-19 vaccination: a multimodality pictorial illustration and review of current guidelines.

Clinical radiology·2021
Same author

An evaluation of patient reported outcomes by utilizing breast Q following oncoplastic breast conserving surgery and arc-LICAP flap partial breast reconstruction.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2020
Same author

Observations on the effects of Suppressor of Cytokine Signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin Like Growth Factor I (IGF-I).

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2013
Same author

Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.

Oncology reports·2013
Same author

Comment on prognostic and therapeutic implications of mTORC2 and rictor expression in human breast cancer.

Breast cancer research and treatment·2012

HER2 overexpression in breast cancer impacts prognosis and treatment response. Trastuzumab (Herceptin) offers a targeted therapy option with a favorable safety profile for HER2-positive metastatic breast cancer.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2 overexpression is present in 25% of breast cancers, associated with poor prognosis.
  • HER2 status influences response to chemotherapy and hormonal therapies like tamoxifen.

Purpose of the Study:

  • To evaluate the efficacy and safety of Trastuzumab (Herceptin) for HER2-overexpressing metastatic breast cancer.
  • To assess Trastuzumab's role as a single agent and in combination therapy.

Main Methods:

  • Pre-clinical studies in mice using monoclonal antibodies.
  • Phase II and III clinical trials in women with metastatic breast cancer.

Main Results:

  • Trastuzumab is effective as a single agent and in combination with paclitaxel for HER2-positive metastatic breast cancer.

Related Experiment Videos

  • Herceptin is well-tolerated, with fewer common chemotherapy side effects.
  • Cardiotoxicity risk is linked to prior anthracycline exposure.

    • Conclusions:

    • Trastuzumab is a valuable targeted therapy for HER2-overexpressing metastatic breast cancer.
    • The drug demonstrates a manageable safety profile, particularly regarding cardiotoxicity.
    • Ongoing research is exploring Trastuzumab's use in the adjuvant setting.